Today: 29 June 2026
Browse Category

LSE:GSK 11 December 2025 - 5 January 2026

London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

London Stock Exchange Poised for Year-End Reopen as FTSE 100 Holds Near 9,871 and 2026 IPO Hopes Build

NEW YORK, Dec. 28, 2025, 7:52 a.m. ET — Market Closed With U.S. stock markets shut for the weekend and London also dark until Monday, investors are heading into the final stretch of 2025 with an unusually familiar year-end cocktail: thin liquidity, big cross-asset moves, and a loud debate over whether London can finally turn “capital markets reform” into actual capital markets.
28 December 2025
···
London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

As of 7:53 a.m. ET in New York on Saturday, December 27, 2025, the London Stock Exchange is closed for the weekend — and it’s also coming off the Christmas holiday break. That timing matters, because the LSE is heading into a classic “thin liquidity” stretch: fewer traders at their desks, wider bid–ask spreads, and price moves that can look louder than the underlying news. The next London session is set to reopen at 8:00 a.m. London time on Monday, December 29, according to the exchange’s own market status display. London Stock Exchange
27 December 2025
···
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

December 26, 2025 — GSK plc stock is closing out the year with a familiar mix of “defensive pharma stability” and “pipeline-driven volatility.” The past two weeks delivered a cluster of headline-worthy updates: a U.S. FDA approval for GSK’s twice-yearly asthma biologic, a high-profile U.S. drug-pricing agreement that directly touches GSK’s respiratory franchise, regulatory momentum for expanded vaccine use in Europe, and fresh competitive noise around Shingrix—one of GSK’s biggest profit engines. This is a stock that rarely moves on vibes alone. For GSK shares, regulatory decisions, pricing frameworks, and evidence that new products can offset looming patent expiries are the levers that matter most. Here’s what’s driving the narrative as of Dec. 26, 2025, plus where forecasts and analyst expectations are clustering for 2026.
26 December 2025
···
UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

London | Friday, 26 December 2025 — The UK stock market is effectively on pause today, with the London Stock Exchange closed for the Boxing Day bank holiday. But “no trading” doesn’t mean “no market story”: investors are spending the day digesting a strong 2025 run for the FTSE 100, fresh signals from the make-or-break retail season, and a global backdrop dominated by a year-end risk rally and a fresh spike in precious metals that could ripple through London-listed miners when UK dealing resumes. Reuters No. London’s stock market is shut on Friday, 26 December for Boxing Day, following the Christmas Day closure. The last UK cash-equities session was the shortened Christmas Eve trade, and the next moves in FTSE-linked prices will be driven mainly by overseas trading until London reopens. Reuters
26 December 2025
·····
UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

London — 25 December 2025. UK investors heading into Friday, 26 December 2025 should start with one practical reality: there is no standard London cash equity session tomorrow. From there, attention shifts to what’s been moving the FTSE 100, the pound, commodities and rate expectations into year-end — and what could matter most when trading resumes. No. The London market is closed on Boxing Day. Several brokers and market schedules list 26 December as a UK market closure, with UK equities not trading in the usual way on that date. IG
25 December 2025
····
United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

London — Thursday, 25 December 2025. The United Kingdom stock market is closed today for Christmas Day, putting a temporary pause on trading after a holiday-shortened run into the break. With the London Stock Exchange also shut on Friday for Boxing Day, the next meaningful read on UK risk appetite will come when markets reopen after the long weekend. MoneyWeek Even with the screens dark, investors are still digesting a busy late-December backdrop: a Bank of England rate cut to 3.75%, a strong year for UK large caps, record-setting moves in industrial metals that boosted miners, and headline corporate deals—most notably BP’s agreement to sell a majority stake in Castrol. Bank of England
25 December 2025
····
GSK plc Stock: Latest News, Share Price Today, Analyst Forecasts and 2026 Outlook (December 24, 2025)

GSK plc Stock: Latest News, Share Price Today, Analyst Forecasts and 2026 Outlook (December 24, 2025)

GSK plc is heading into the year-end stretch with an unusually busy mix of policy headlines, regulatory wins, and capital-return updates—exactly the kind of combo that can make a “defensive” pharma stock behave a little less like a sleepy utility and a little more like… well, a stock that has catalysts. On Christmas Eve, liquidity is thinner than usual because both the London and U.S. markets run shortened hours. The London Stock Exchange closes early at 12:30 p.m. UK time, and the NYSE/Nasdaq close early at 1:00 p.m. ET. MoneyWeek+1
24 December 2025
··
GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc heads into the weekend with a rare “everything-bagel” mix of catalysts: a new U.S. drug-pricing agreement tied to tariff relief, a fresh FDA approval that could reshape severe-asthma dosing schedules, expanding vaccine indications in Europe, and a steady drumbeat of buybacks. For investors tracking GSK stock, the headline isn’t just one event—it’s the way policy, pipeline, and capital returns are colliding in the same two-week window. Because December 20, 2025 is a Saturday, markets are closed. In U.S. trading, GSK’s ADR last closed on Friday, Dec. 19 at $48.61. StockAnalysis
20 December 2025
···
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK plc is ending 2025 with a busy headline tape—exactly the kind of environment where investors tend to re-check both the “story” and the spreadsheet. On Thursday, December 18, 2025, GSK published a fresh share buyback update, while markets continue to digest a string of regulatory milestones across respiratory, vaccines, and infectious diseases that could shape the company’s growth profile into 2026. Below is what’s new as of 18.12.2025, what analysts are forecasting, and what matters most for GSK stock next.
18 December 2025
··
GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc announced today that the FDA approved Exdensur for severe eosinophilic asthma in patients 12+. Here’s what it means for GSK’s respiratory pipeline, competition, and shareholders on 17.12.2025. GSK plc is in the spotlight on Wednesday, 17 December 2025, after the company confirmed US FDA approval for Exdensur—a new twice‑yearly biologic for severe asthma—while also releasing its latest share buyback update through a regulatory filing. Investegate+1
17 December 2025
···
GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

Updated: 17 December 2025 GSK plc stock is in focus on Dec. 17 after a major U.S. regulatory win: the FDA approved Exdensur for severe asthma—giving GSK a new, ultra‑long‑acting biologic that’s dosed just twice a year. The approval lands as the company approaches a leadership handover on Jan. 1, 2026, and as investors weigh whether GSK’s late‑2025 pipeline momentum can translate into durable earnings growth in 2026 and beyond. Reuters+2GSK+2
17 December 2025
··
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

December 16, 2025 — GSK plc stock is firmly on investors’ radar today after a cluster of late-year regulatory catalysts across respiratory, vaccines, and infectious diseases — the kind of headline flow that can reshape sentiment around a large-cap biopharma even when quarterly earnings are weeks away. In the latest available market data, GSK’s US-listed ADR traded around $49.24. Meanwhile, in London, GSK shares most recently closed at 1,833.50p on Dec. 15, up 0.49% on the day, with the Financial Times’ market data showing a ~+37.9% one-year change. FT Markets
16 December 2025
··
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts: FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead GSK plc stock is ending 2025 with a rare “cluster” of market-moving catalysts packed into the same two-week window: fresh U.S. regulatory momentum for a new antibiotic, European regulatory backing for multiple respiratory products, and an imminent FDA decision that could reshape GSK’s long-term outlook in severe asthma and nasal polyps.
15 December 2025
··
GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

Updated: Sunday, December 14, 2025. GSK plc heads into mid‑December with a rare “cluster catalyst” setup: multiple fresh European regulator panel endorsements, a new U.S. label expansion for an antibiotic, and steady buyback activity. That combination doesn’t guarantee a breakout, but it does give investors a clearer map of what could move GSK shares in the days ahead.
14 December 2025
···
GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus

GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus

Updated: December 13, 2025 GSK plc is ending the week in the spotlight after a cluster of regulatory updates in Europe and the United States—exactly the kind of “catalyst stacking” that can shift the narrative around a big pharma stock from defensive dividend name to pipeline and launch execution story. Add in an active share buyback program, a clearly mapped dividend calendar, and an incoming CEO transition in early 2026, and GSK stock has plenty for investors to digest heading into year-end. GSK+3Reuters+3Reuters+3
13 December 2025
··
GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

On 11 December 2025, outgoing GSK chief executive Dame Emma Walmsley sent a stark message to Westminster and the City: for big drug makers, the United States is now the premier destination for investment – and Britain is at risk of slipping further behind. In a broadcast interview, Walmsley praised the US as the world’s most attractive market for new medicines, saying it remains the leading arena for launching innovative drugs and vaccines and the “best place to invest” for global pharma. She also pointed to China as the other key growth market for business development. The Guardian+1
11 December 2025
··
GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK Stock (LON:GSK, NYSE:GSK): Latest News, FDA Catalysts and 2026 Outlook – December 11, 2025

GSK plc stock has quietly morphed from a problem child of Big Pharma into one of 2025’s more interesting “value with growth” stories. The shares are trading near multi‑year highs, the company has upgraded guidance, big litigation overhangs are easing, and a cluster of U.S. FDA decisions is about to test how much of that optimism is justified. As of last night’s close, GSK’s U.S. ADR finished at $48.40, up more than 45% year‑to‑date, while the London‑listed shares recently changed hands around 1,800p, having pushed above their 200‑day moving average of 1,547.73p on heavy volume. MarketBeat+1
11 December 2025
·
1 2 3 4

Stock Market Today

  • SPS Commerce (SPSC) Rallies 5.7% on Sale Rumors, Earnings in Focus
    June 29, 2026, 2:05 PM EDT. SPS Commerce (SPSC) closed up 5.7% at $58.87 after volume spiked and reports spread about a possible sale, tied to activist pressure for the company to consider strategic options. The supply chain software firm forecasts quarterly EPS of $1.08, up 8% from last year, and sees revenue at $195.14 million, up 4.1%. Consensus estimates for earnings didn't move in the last 30 days, which could cap upside ahead. SPSC sits at Zacks Rank #2 (Buy). Bowman Consulting (BWMN), another name in the group, climbed 2.3% but has seen its earnings estimates drop 14.6%; Zacks Rank is #3 (Hold). Market watching for shifts in earnings outlooks for clues on next moves.
Go toTop